Literature DB >> 27497989

Cell-specific paracrine actions of IL-6 family cytokines from bone, marrow and muscle that control bone formation and resorption.

Natalie A Sims1.   

Abstract

Bone renews itself and changes shape throughout life to account for the changing needs of the body; this requires co-ordinated activities of bone resorbing cells (osteoclasts), bone forming cells (osteoblasts) and bone's internal cellular network (osteocytes). This review focuses on paracrine signaling by the IL-6 family of cytokines between bone cells, bone marrow, and skeletal muscle in normal physiology and in pathological states where their levels may be locally or systemically elevated. These functions include the support of osteoclast formation by osteoblast lineage cells in response to interleukin 6 (IL-6), interleukin 11 (IL-11), oncostatin M (OSM) and cardiotrophin 1 (CT-1). In addition it will discuss how bone-resorbing osteoclasts promote osteoblast activity by secreting CT-1, which acts as a "coupling factor" on osteocytes, osteoblasts, and their precursors to promote bone formation. OSM, produced by osteoblast lineage cells and macrophages, stimulates bone formation via osteocytes. IL-6 family cytokines also mediate actions of other bone formation stimuli like parathyroid hormone (PTH) and mechanical loading. CT-1, OSM and LIF suppress marrow adipogenesis by shifting commitment of pluripotent precursors towards osteoblast differentiation. Ciliary neurotrophic factor (CNTF) is released as a myokine from skeletal muscle and suppresses osteoblast differentiation and bone formation on the periosteum (outer bone surface in apposition to muscle). Finally, IL-6 acts directly on marrow-derived osteoclasts to stimulate release of "osteotransmitters" that act through the cortical osteocyte network to stimulate bone formation on the periosteum. Each will be discussed as illustrations of how the extended family of IL-6 cytokines acts within the skeleton in physiology and may be altered in pathological conditions or by targeted therapies.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Gp130; Il6st; Osteoblast; Osteoclast; Osteocyte

Mesh:

Substances:

Year:  2016        PMID: 27497989     DOI: 10.1016/j.biocel.2016.08.003

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  33 in total

Review 1.  IL-6 blockade in the management of non-infectious uveitis.

Authors:  Giuseppe Lopalco; Claudia Fabiani; Jurgen Sota; Orso Maria Lucherini; Gian Marco Tosi; Bruno Frediani; Florenzo Iannone; Mauro Galeazzi; Rossella Franceschini; Donato Rigante; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2017-05-20       Impact factor: 2.980

Review 2.  Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.

Authors:  Giovanni Lombardi; Mosè Barbaro; Massimo Locatelli; Giuseppe Banfi
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

3.  Blocking gp130 signaling suppresses autotaxin expression in adipocytes and improves insulin sensitivity in diet-induced obesity.

Authors:  Shuhong Sun; Ran Wang; Jianwen Song; Ming Guan; Na Li; Xiaotian Zhang; Zhenwen Zhao; Junjie Zhang
Journal:  J Lipid Res       Date:  2017-09-05       Impact factor: 5.922

4.  Osteoblasts Are Rapidly Ablated by Virus-Induced Systemic Inflammation following Lymphocytic Choriomeningitis Virus or Pneumonia Virus of Mice Infection in Mice.

Authors:  Steven Maltby; Alyssa J Lochrin; Bianca Bartlett; Hock L Tay; Jessica Weaver; Ingrid J Poulton; Maximilian W Plank; Helene F Rosenberg; Natalie A Sims; Paul S Foster
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

5.  Interleukin-6 (IL-6) deficiency enhances intramembranous osteogenesis following stress fracture in mice.

Authors:  Brandon A Coates; Jennifer A McKenzie; Susumu Yoneda; Matthew J Silva
Journal:  Bone       Date:  2020-11-10       Impact factor: 4.398

Review 6.  Role of fibro-adipogenic progenitor cells in muscle atrophy and musculoskeletal diseases.

Authors:  Emily Parker; Mark W Hamrick
Journal:  Curr Opin Pharmacol       Date:  2021-04-08       Impact factor: 4.768

Review 7.  Muscle-Bone Crosstalk: Emerging Opportunities for Novel Therapeutic Approaches to Treat Musculoskeletal Pathologies.

Authors:  Delphine B Maurel; Katharina Jähn; Nuria Lara-Castillo
Journal:  Biomedicines       Date:  2017-10-24

8.  The effect of age on the microarchitecture and profile of gene expression in femoral head and neck bone from patients with osteoarthritis.

Authors:  Dorit Naot; Maureen Watson; Ally J Choi; David S Musson; Karen E Callon; Mark Zhu; Ryan Gao; William Caughey; Rocco P Pitto; Jacob T Munro; Anne Horne; Gregory D Gamble; Nicola Dalbeth; Ian R Reid; Jillian Cornish
Journal:  Bone Rep       Date:  2020-06-05

Review 9.  Long-term Consequences of Traumatic Brain Injury in Bone Metabolism.

Authors:  Nikita M Bajwa; Chandrasekhar Kesavan; Subburaman Mohan
Journal:  Front Neurol       Date:  2018-03-05       Impact factor: 4.003

10.  IL-6 potentiates BMP-2-induced osteogenesis and adipogenesis via two different BMPR1A-mediated pathways.

Authors:  Ru-Lin Huang; Yangbai Sun; Chia-Kang Ho; Kai Liu; Qi-Qun Tang; Yun Xie; Qingfeng Li
Journal:  Cell Death Dis       Date:  2018-02-02       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.